Sign in
CompletedPhase 3

Estrogen and Fear in PTSD

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Where
Houston and Philadelphia, United StatesSee the 2 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
83 people enrolled
Started
24 Jun 2020
Ended
2 Dec 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Estradiol
  • Placebo oral tablet
  • Prolonged Exposure (PE) therapy
Record updated
9 January 2026

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Female, 18-45 years of age
  • Chronic (at least one month post-trauma) DSM-5 FULL PTSD diagnosis OR subPTSD diagnosis (subPTSD defined as: meeting criterion A, F, G, H, and clusters B, C, and at least 1 of the clusters D or E.)
  • CAPS-5 Past Month score ≥ 20
  • Criterion A traumatic event
  • Stable medications for 3 or more months by the time of study entrance (with the exception of benzodiazepines)
  • Women on oral contraceptives, specifically those using monophasic or biphasic of first, second, third or fourth generation with up to 35mcg of ethinyl estradiol; OR using etonogestrel / ethinyl estradiol 0.120mg/0.015mg per day vaginal ring birth control; OR using the norelgestromin / ethinyl estradiol 0.150mg/0.035mg per day transdermal patch birth control
  • Willing and able to provide informed consent

Who cannot take part

  • Concurrent trauma focused psychotherapy
  • Metallic implants or devices contraindicating magnetic resonance imaging by interfering with patient safety or fMRI data collection. Cases will be cleared by the Principal Investigator and/or Baylor College of Medicine (Imaging)
  • Diagnosis of bipolar I disorder with a past year manic episode
  • Diagnosis of a psychotic disorder or psychotic symptoms that would interfere with the ability to focus on posttraumatic stress disorder (PTSD) in clinic, as determined by clinical judgment
  • Diagnosis of moderate or severe substance use disorder that would interfere with the ability to focus on posttraumatic stress disorder (PTSD) in clinic, as determined by clinical judgment
  • Cognitive impairment that would interfere with the ability to focus on posttraumatic stress disorder (PTSD) in clinic, as determined by clinical judgment
  • History of neurological disease (that involves the brain), seizure, or significant head trauma (i.e., extended loss of consciousness, neurological sequelae, or known structural brain lesion)
  • History of breast cancer or hormone-responsive cancer
  • High risk of adverse emotional or behavioral reaction, and/or an inability to understand study procedures or the informed consent process, based on investigator/clinician clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, lack of meaningful social support)
  • Suicidal ideation with imminent risk that warrants a higher level of care
  • Pregnancy (to be ruled out by urine ß-HCG)
  • Use of benzodiazepines
  • Self-injurious behavior that involves suicidal intent, requires medical attention, or occurs daily

Where in United States

  • The University of Texas Health Science Center at Houston (UTHealth Houston)Houston, United States
  • University of Pennsylvania Perelman School of MedicinePhiladelphia, United States

About the trial

What the trial wants to find out

The purpose of this research study is to determine if taking a pill of estradiol (E2) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). 80 subjects will take part in this research study across UTHealth Houston and UPenn (40 subjects at each site). Participants will be randomized into one of two groups, PE + E2 or PE + placebo. The study will include preliminary screening and baseline visits, experimental visits, and therapy visits over the course of six weeks. Several follow-up visits will take place.

The 2 groups in the trial

  • Prolonged Exposure (PE) therapy with EstradiolTreatment being tested

    A single 2mg dose of estradiol (a form of estrogen) will be taken at home by the study participant 5-6 hours before each of 5 prolonged exposure (PE) therapy treatment sessions (sessions 2 to 6). PE therapy is a validated treatment for PTSD.

    Treatment: Estradiol and Prolonged Exposure (PE) therapy

  • Prolonged Exposure (PE) therapy with PlaceboPlacebo, for comparison

    A single 2mg placebo pill will be taken at home by the study participant 5-6 hours before each of 5 prolonged exposure (PE) therapy treatment sessions (sessions 2 to 6). PE therapy is a validated treatment for PTSD.

    Treatment: Placebo oral tablet and Prolonged Exposure (PE) therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind Placebo-controlled Multi-center Study of Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Combined Estrogen and Prolonged Exposure Therapy
Record updated
9 January 2026